160 related articles for article (PubMed ID: 21420886)
1. Utility of cytokeratin 5/6 and high-molecular-weight keratin in evaluation of cauterized surgical margins in excised specimens of breast ductal carcinoma in situ.
Nayak A; Bhuiya TA
Ann Diagn Pathol; 2011 Aug; 15(4):243-9. PubMed ID: 21420886
[TBL] [Abstract][Full Text] [Related]
2. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
3. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
4. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.
Grin A; O'Malley FP; Mulligan AM
Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450
[TBL] [Abstract][Full Text] [Related]
6. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
[TBL] [Abstract][Full Text] [Related]
7. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
8. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
Macdonald HR; Silverstein MJ; Lee LA; Ye W; Sanghavi P; Holmes DR; Silberman H; Lagios M
Am J Surg; 2006 Oct; 192(4):420-2. PubMed ID: 16978941
[TBL] [Abstract][Full Text] [Related]
9. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
10. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
[TBL] [Abstract][Full Text] [Related]
11. Optimal use of re-excision in patients diagnosed with early-stage breast cancer by excisional biopsy treated with breast-conserving therapy.
Caughran JL; Vicini FA; Kestin LL; Dekhne NS; Benitez PR; Goldstein NS
Ann Surg Oncol; 2009 Nov; 16(11):3020-7. PubMed ID: 19636632
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis.
Simooka H; Oyama T; Sano T; Horiguchi J; Nakajima T
Pathol Int; 2004 Aug; 54(8):595-602. PubMed ID: 15260850
[TBL] [Abstract][Full Text] [Related]
14. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor.
Xu S; Wei B; Zhang H; Qing M; Bu H
Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
17. The effect of margins on the clinical management of ductal carcinoma in situ of the breast.
Meijnen P; Gilhuijs KG; Rutgers EJ
J Surg Oncol; 2008 Dec; 98(8):579-84. PubMed ID: 19072848
[TBL] [Abstract][Full Text] [Related]
18. Extent and histologic pattern of atypical ductal hyperplasia present on core needle biopsy specimens of the breast can predict ductal carcinoma in situ in subsequent excision.
Wagoner MJ; Laronga C; Acs G
Am J Clin Pathol; 2009 Jan; 131(1):112-21. PubMed ID: 19095574
[TBL] [Abstract][Full Text] [Related]
19. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting successful breast conservation for ductal carcinoma in situ.
Dillon MF; Mc Dermott EW; O'Doherty A; Quinn CM; Hill AD; O'Higgins N
Ann Surg Oncol; 2007 May; 14(5):1618-28. PubMed ID: 17443388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
